Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - Aug 14, 2024 - "UPCOMING EVENTS AND MILESTONES:...(i) Complete ReSPECT-LM Phase 1 single administration trial and determine the recommended Phase 2 dose; (ii) Initiate ReSPECT-LM Phase 1 multiple administration trial; (iii) Obtain IND approval for a Phase 1/2 trial of Rhenium (186Re) Obisbemeda via convection enhanced delivery (CED) funded by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP) for pediatric ependymoma and high-grade glioma."
IND • Trial status • Ependymoma • Glioma
|